HSAN1 mutations in serine palmitoyltransferase reveal a close structure–function–phenotype relationship
Open Access
- 17 December 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 25 (5), 853-865
- https://doi.org/10.1093/hmg/ddv611
Abstract
Hereditary sensory and autonomic neuropathy type 1 (HSAN1) is a rare autosomal dominant inherited peripheral neuropathy caused by mutations in the SPTLC1 and SPTLC2 subunits of serine palmitoyltransferase (SPT). The mutations induce a permanent shift in the substrate preference from l-serine to l-alanine, which results in the pathological formation of atypical and neurotoxic 1-deoxy-sphingolipids (1-deoxySL). Here we compared the enzymatic properties of 11 SPTLC1 and six SPTLC2 mutants using a uniform isotope labelling approach. In total, eight SPT mutants (STPLC1p.C133W, p.C133Y, p.S331F, p.S331Y and SPTLC2p.A182P, p.G382V, p.S384F, p.I504F) were associated with increased 1-deoxySL synthesis. Despite earlier reports, canonical activity with l-serine was not reduced in any of the investigated SPT mutants. Three variants (SPTLC1p.S331F/Y and SPTLC2p.I505Y) showed an increased canonical activity and increased formation of C20 sphingoid bases. These three mutations are associated with an exceptionally severe HSAN1 phenotype, and increased C20 sphingosine levels were also confirmed in plasma of patients. A principal component analysis of the analysed sphingoid bases clustered the mutations into three separate entities. Each cluster was related to a distinct clinical outcome (no, mild and severe HSAN1 phenotype). A homology model based on the protein structure of the prokaryotic SPT recapitulated the same grouping on a structural level. Mutations associated with the mild form clustered around the active site, whereas mutations associated with the severe form were located on the surface of the protein. In conclusion, we showed that HSAN1 mutations in SPT have distinct biochemical properties, which allowed for the prediction of the clinical symptoms on the basis of the plasma sphingoid base profile.Keywords
Funding Information
- the 7th Framework Program of the European Commission (305707)
- Swiss National Foundation SNF (31003A_153390/1)
- Hurka Foundation, the Novartis Foundation and the Rare Disease Initiative Zurich (‘radiz’, Clinical Research Priority Program for Rare Diseases, University of Zurich)
This publication has 60 references indexed in Scilit:
- A de novo gain-of-function mutation in SCN11A causes loss of pain perceptionNature Genetics, 2013
- Hereditary sensory autonomic neuropathy caused by a mutation in dystoninAnnals of Neurology, 2012
- Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing lossNature Genetics, 2011
- Targeted High-Throughput Sequencing Identifies Mutations in atlastin-1 as a Cause of Hereditary Sensory Neuropathy Type IAmerican Journal of Human Genetics, 2011
- Mutations in the SPTLC2 Subunit of Serine Palmitoyltransferase Cause Hereditary Sensory and Autonomic Neuropathy Type IAmerican Journal of Human Genetics, 2010
- Hereditary sensory neuropathy type IOrphanet Journal of Rare Diseases, 2008
- Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I)Brain, 2005
- SPTLC1 is mutated in hereditary sensory neuropathy, type 1Nature Genetics, 2001
- Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type INature Genetics, 2001
- HEREDITARY SENSORY RADICULAR NEUROPATHYJournal of Neurology, Neurosurgery & Psychiatry, 1951